Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
TCRT Alaunos Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: TCRT
Price (delayed)
$2.6888
Market cap
$4.41M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.54
Enterprise value
$4.09M
Ziopharm Oncology is an immuno-oncology company focused on developing end-to-endcost-effective solutions using its non-viralSleeping Beauty platform for TCR and CAR T-cell therapies and immune-stimulating gene therapy with Controlled interleukin 12
Highlights
TCRT's net income has surged by 85% year-on-year and by 13% since the previous quarter
Alaunos Therapeutics's EPS has soared by 85% YoY and by 13% from the previous quarter
The gross profit has surged by 60% year-on-year but it has declined by 20% since the previous quarter
The revenue has soared by 60% YoY but it has contracted by 20% from the previous quarter
The company's quick ratio has shrunk by 91% YoY and by 81% QoQ
TCRT's equity has shrunk by 78% YoY and by 49% QoQ
Key stats
What are the main financial stats of TCRT
Market
Valuations
Earnings
Shares outstanding
1.64M
Market cap
$4.41M
Enterprise value
$4.09M
Price to earnings (P/E)
N/A
Price to book (P/B)
4.07
Price to sales (P/S)
538.18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
511.17
Revenue
$8,000
Gross profit
$8,000
Operating income
-$4.17M
Net income
-$4.07M
EBIT
-$4.07M
EBITDA
-$4.07M
Free cash flow
-$3.83M
Per share
Balance sheet
Liquidity
EPS
-$2.54
EPS diluted
-$2.54
Free cash flow per share
-$2.39
Book value per share
$0.66
Revenue per share
$0
TBVPS
$1.32
Total assets
$2.12M
Total liabilities
$1.06M
Debt
$0
Equity
$1.06M
Working capital
$5,000
Debt to equity
0
Current ratio
1
Quick ratio
0.3
Net debt/EBITDA
0.08
Margins
Efficiency
Dividend
EBITDA margin
-50,887.5%
Gross margin
100%
Net margin
-50,887.5%
Operating margin
-52,062.5%
Return on assets
-124.3%
Return on equity
-169.3%
Return on invested capital
-401.1%
Return on capital employed
-384.8%
Return on sales
-50,887.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TCRT stock price
How has the Alaunos Therapeutics stock price performed over time
Intraday
-3.63%
1 week
8.42%
1 month
6.28%
1 year
-75.1%
YTD
41.14%
QTD
82.91%
Financial performance
How have Alaunos Therapeutics's revenue and profit performed over time
Revenue
$8,000
Gross profit
$8,000
Operating income
-$4.17M
Net income
-$4.07M
Gross margin
100%
Net margin
-50,887.5%
The operating margin has soared by 90% YoY but it has decreased by 8% from the previous quarter
Alaunos Therapeutics's net margin has soared by 90% YoY but it has decreased by 9% from the previous quarter
TCRT's net income has surged by 85% year-on-year and by 13% since the previous quarter
The company's operating income has surged by 84% YoY and by 13% QoQ
Price vs fundamentals
How does TCRT's price correlate with its fundamentals
Growth
What is Alaunos Therapeutics's growth rate over time
Valuation
What is Alaunos Therapeutics stock price valuation
P/E
N/A
P/B
4.07
P/S
538.18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
511.17
Alaunos Therapeutics's EPS has soared by 85% YoY and by 13% from the previous quarter
The price to book (P/B) is 94% higher than the last 4 quarters average of 2.1 but 12% lower than the 5-year quarterly average of 4.6
TCRT's equity has shrunk by 78% YoY and by 49% QoQ
The revenue has soared by 60% YoY but it has contracted by 20% from the previous quarter
The price to sales (P/S) is 44% lower than the last 4 quarters average of 967.3
Efficiency
How efficient is Alaunos Therapeutics business performance
Alaunos Therapeutics's ROS has soared by 90% YoY but it has decreased by 9% from the previous quarter
The ROIC has soared by 57% YoY and by 15% QoQ
The company's return on assets rose by 28% YoY but it fell by 13% QoQ
The return on equity has grown by 26% year-on-year but it has declined by 21% since the previous quarter
Dividends
What is TCRT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TCRT.
Financial health
How did Alaunos Therapeutics financials performed over time
The total assets is 100% more than the total liabilities
The company's quick ratio has shrunk by 91% YoY and by 81% QoQ
Alaunos Therapeutics's current ratio has plunged by 79% YoY and by 75% from the previous quarter
Alaunos Therapeutics's debt is 100% less than its equity
TCRT's equity has shrunk by 78% YoY and by 49% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.